JP2014524009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524009A5 JP2014524009A5 JP2014502870A JP2014502870A JP2014524009A5 JP 2014524009 A5 JP2014524009 A5 JP 2014524009A5 JP 2014502870 A JP2014502870 A JP 2014502870A JP 2014502870 A JP2014502870 A JP 2014502870A JP 2014524009 A5 JP2014524009 A5 JP 2014524009A5
- Authority
- JP
- Japan
- Prior art keywords
- akt
- mutation
- cell
- tumor cells
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 70
- 230000035772 mutation Effects 0.000 claims description 47
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 35
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 20
- 230000035945 sensitivity Effects 0.000 claims description 18
- 230000003993 interaction Effects 0.000 claims description 16
- 230000026731 phosphorylation Effects 0.000 claims description 15
- 238000006366 phosphorylation reaction Methods 0.000 claims description 15
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 13
- 108091007960 PI3Ks Proteins 0.000 claims description 13
- 229940126638 Akt inhibitor Drugs 0.000 claims description 11
- 108091000080 Phosphotransferase Proteins 0.000 claims description 11
- 102000020233 phosphotransferase Human genes 0.000 claims description 11
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical group C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 7
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 230000004565 tumor cell growth Effects 0.000 claims description 3
- 230000002596 correlated effect Effects 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 31
- 210000004881 tumor cell Anatomy 0.000 claims 19
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 2
- FPYJSJDOHRDAMT-KQWNVCNZSA-N 1h-indole-5-sulfonamide, n-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1h-pyrrol-2-yl]methylene]-2,3-dihydro-n-methyl-2-oxo-, (3z)- Chemical compound C=1C=C2NC(=O)\C(=C/C3=C(C(C(=O)N4CCN(C)CC4)=C(C)N3)C)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FPYJSJDOHRDAMT-KQWNVCNZSA-N 0.000 claims 2
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 101710113436 GTPase KRas Proteins 0.000 claims 2
- 101001053339 Homo sapiens Inositol polyphosphate 4-phosphatase type II Proteins 0.000 claims 2
- 101001129621 Homo sapiens PH domain leucine-rich repeat-containing protein phosphatase 1 Proteins 0.000 claims 2
- 102100024366 Inositol polyphosphate 4-phosphatase type II Human genes 0.000 claims 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 2
- 102100031152 PH domain leucine-rich repeat-containing protein phosphatase 1 Human genes 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 claims 1
- 230000007711 cytoplasmic localization Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 102200085788 rs121913279 Human genes 0.000 claims 1
- 102200085789 rs121913279 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 description 10
- 230000003281 allosteric effect Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102200093329 rs121434592 Human genes 0.000 description 8
- 206010069754 Acquired gene mutation Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000037439 somatic mutation Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 101150045355 akt1 gene Proteins 0.000 description 2
- 230000001908 autoinhibitory effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- 102220573865 Adenosine receptor A2a_V83D_mutation Human genes 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 description 1
- 102220493783 HLA class II histocompatibility antigen, DRB1 beta chain_F55Y_mutation Human genes 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000690268 Homo sapiens Proline-rich AKT1 substrate 1 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 102220515882 M-phase phosphoprotein 8_W80A_mutation Human genes 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 101000779417 Mus musculus RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 102220569749 Programmed cell death protein 6_L52A_mutation Human genes 0.000 description 1
- 102100024091 Proline-rich AKT1 substrate 1 Human genes 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102220495915 Serine-tRNA ligase, cytoplasmic_N54A_mutation Human genes 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- -1 pAKT Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471036P | 2011-04-01 | 2011-04-01 | |
| US61/471,036 | 2011-04-01 | ||
| PCT/US2012/031662 WO2012135749A2 (en) | 2011-04-01 | 2012-03-30 | Biomarkers for predicting sensitivity to cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201976A Division JP2018050625A (ja) | 2011-04-01 | 2017-10-18 | 癌治療に対する感受性を予測するためのバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524009A JP2014524009A (ja) | 2014-09-18 |
| JP2014524009A5 true JP2014524009A5 (https=) | 2017-11-30 |
| JP6293655B2 JP6293655B2 (ja) | 2018-03-14 |
Family
ID=46932419
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502870A Active JP6293655B2 (ja) | 2011-04-01 | 2012-03-30 | 癌治療に対する感受性を予測するためのバイオマーカー |
| JP2017201976A Pending JP2018050625A (ja) | 2011-04-01 | 2017-10-18 | 癌治療に対する感受性を予測するためのバイオマーカー |
| JP2019165545A Active JP7044746B2 (ja) | 2011-04-01 | 2019-09-11 | 癌治療に対する感受性を予測するためのバイオマーカー |
| JP2022042069A Withdrawn JP2022095670A (ja) | 2011-04-01 | 2022-03-17 | 癌治療に対する感受性を予測するためのバイオマーカー |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201976A Pending JP2018050625A (ja) | 2011-04-01 | 2017-10-18 | 癌治療に対する感受性を予測するためのバイオマーカー |
| JP2019165545A Active JP7044746B2 (ja) | 2011-04-01 | 2019-09-11 | 癌治療に対する感受性を予測するためのバイオマーカー |
| JP2022042069A Withdrawn JP2022095670A (ja) | 2011-04-01 | 2022-03-17 | 癌治療に対する感受性を予測するためのバイオマーカー |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20140031259A1 (https=) |
| EP (2) | EP2694959B8 (https=) |
| JP (4) | JP6293655B2 (https=) |
| KR (2) | KR102165122B1 (https=) |
| CN (1) | CN103858007B (https=) |
| AU (1) | AU2012236134A1 (https=) |
| BR (1) | BR112013025356B1 (https=) |
| CA (1) | CA2850175C (https=) |
| ES (1) | ES2768081T3 (https=) |
| IL (1) | IL228636A0 (https=) |
| MX (1) | MX348655B (https=) |
| PL (1) | PL2694959T3 (https=) |
| RU (1) | RU2635193C2 (https=) |
| SG (2) | SG10201507582VA (https=) |
| WO (1) | WO2012135749A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012135781A1 (en) * | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| PL2694959T3 (pl) * | 2011-04-01 | 2020-05-18 | Genentech, Inc. | Biomarkery do przewidywania wrażliwości w leczeniu nowotworu złośliwego |
| EP2959014B1 (en) | 2013-02-25 | 2019-11-13 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
| US20170290849A1 (en) * | 2014-09-05 | 2017-10-12 | The Trustees Of Columbia University In The City Of New York | AKT and SHH Pathway Inhibitor Combination Therapy for Treating Basal Cell Carcinomas |
| BR112017007962A2 (pt) * | 2014-10-24 | 2018-01-23 | Koninklijke Philips Nv | método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit |
| CN106783976A (zh) * | 2016-12-12 | 2017-05-31 | 东莞市广信知识产权服务有限公司 | 一种GaN沟道MOS界面结构 |
| KR102129532B1 (ko) * | 2018-07-19 | 2020-07-02 | 조성은 | Pten 억제제에 대한 췌장암 치료 반응성 예측용 바이오마커 및 이의 용도 |
| WO2020252455A1 (en) * | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| CN113025713B (zh) * | 2021-02-23 | 2022-11-22 | 浙江东睿生物科技有限公司 | 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| WO1995011995A1 (en) * | 1993-10-26 | 1995-05-04 | Affymax Technologies N.V. | Arrays of nucleic acid probes on biological chips |
| EP2369007B1 (en) | 1996-05-29 | 2015-07-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| AU2001265121A1 (en) | 2000-05-30 | 2001-12-11 | Applera Corporation | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
| EP1496981A2 (en) * | 2002-04-08 | 2005-01-19 | Merck & Co., Inc. | Method of treating cancer |
| WO2004110356A2 (en) * | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| UA95641C2 (xx) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| WO2008049022A2 (en) | 2006-10-18 | 2008-04-24 | Translational Genomics Research Institute | Methods for detection of cancer |
| WO2009006567A2 (en) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| CA2695330C (en) * | 2007-07-12 | 2017-06-13 | University Of South Florida | Inhibitors of akt/pkb with anti-tumor activity |
| WO2009103790A2 (en) * | 2008-02-21 | 2009-08-27 | Universite Libre De Bruxelles | Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications |
| PL2694959T3 (pl) * | 2011-04-01 | 2020-05-18 | Genentech, Inc. | Biomarkery do przewidywania wrażliwości w leczeniu nowotworu złośliwego |
-
2012
- 2012-03-30 PL PL12765178T patent/PL2694959T3/pl unknown
- 2012-03-30 RU RU2013148814A patent/RU2635193C2/ru active
- 2012-03-30 JP JP2014502870A patent/JP6293655B2/ja active Active
- 2012-03-30 KR KR1020197001837A patent/KR102165122B1/ko not_active Expired - Fee Related
- 2012-03-30 KR KR1020137029129A patent/KR102016182B1/ko not_active Expired - Fee Related
- 2012-03-30 MX MX2013011334A patent/MX348655B/es active IP Right Grant
- 2012-03-30 CA CA2850175A patent/CA2850175C/en active Active
- 2012-03-30 BR BR112013025356-8A patent/BR112013025356B1/pt not_active IP Right Cessation
- 2012-03-30 US US14/009,317 patent/US20140031259A1/en not_active Abandoned
- 2012-03-30 SG SG10201507582VA patent/SG10201507582VA/en unknown
- 2012-03-30 SG SG2013073762A patent/SG194050A1/en unknown
- 2012-03-30 ES ES12765178T patent/ES2768081T3/es active Active
- 2012-03-30 EP EP12765178.4A patent/EP2694959B8/en active Active
- 2012-03-30 WO PCT/US2012/031662 patent/WO2012135749A2/en not_active Ceased
- 2012-03-30 EP EP19203410.6A patent/EP3617330B1/en active Active
- 2012-03-30 AU AU2012236134A patent/AU2012236134A1/en not_active Abandoned
- 2012-03-30 CN CN201280027029.8A patent/CN103858007B/zh active Active
-
2013
- 2013-09-30 IL IL228636A patent/IL228636A0/en unknown
-
2016
- 2016-08-15 US US15/237,412 patent/US20170065588A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201976A patent/JP2018050625A/ja active Pending
-
2018
- 2018-09-05 US US16/122,713 patent/US20180360835A1/en not_active Abandoned
-
2019
- 2019-09-11 JP JP2019165545A patent/JP7044746B2/ja active Active
-
2022
- 2022-03-17 JP JP2022042069A patent/JP2022095670A/ja not_active Withdrawn
-
2024
- 2024-09-27 US US18/900,236 patent/US20250281489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524009A5 (https=) | ||
| Corless et al. | Gastrointestinal stromal tumours: origin and molecular oncology | |
| Milowsky et al. | Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma | |
| Jhaveri et al. | The evolution of cyclin dependent kinase inhibitors in the treatment of cancer | |
| Santarpia et al. | Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy | |
| Spring et al. | Targeting the cyclin D–cyclin-dependent kinase (CDK) 4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions | |
| Coleman et al. | Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine | |
| Eng et al. | Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas | |
| Noguchi et al. | Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics | |
| Bose et al. | Activating HER2 mutations in HER2 gene amplification negative breast cancer | |
| Miller et al. | MEK1/2 inhibitors in the treatment of gynecologic malignancies | |
| Passiglia et al. | KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges | |
| Sun et al. | Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies | |
| Mena et al. | Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib | |
| Iyer et al. | Fibroblast growth factor receptor-3 in urothelial tumorigenesis | |
| Stottrup et al. | Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast cancer | |
| Hrustanovic et al. | Mechanisms of resistance to EGFR targeted therapies | |
| Pesch et al. | Short-term CDK4/6 inhibition radiosensitizes estrogen receptor–positive breast cancers | |
| Groen et al. | A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) | |
| Roper et al. | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer | |
| Umesalma et al. | RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth | |
| Wong et al. | Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K–Akt oncogenic dependence in pancreatic ductal adenocarcinoma | |
| Venkatakrishnan et al. | Dose selection for the investigational anticancer agent alisertib (MLN8237): pharmacokinetics, pharmacodynamics, and exposure–safety relationships | |
| Pan et al. | Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer | |
| Nakata et al. | Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer |